Bromodomain containing protein 4 (BRD4) is a reader of epigenetic marks and a key target in oncology [1, 2], inflammation [3, 4] and cardiovascular disease [5] with several inhibitors currently in clinical trials [6–9]. The gene discussed is BRD4; the disease is cardiovascular disorder.